We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us

Download Mobile App




Biologic Data Analysis Software

By Biotechdaily staff writers
Posted on 31 Aug 2005
New data analysis software for researchers enables combined analysis of different data sets and facilitates biologic interpretation of results through public and local database retrieval.

The deCyder Extended Data Analysis (EDA) version 1.0, developed by GE Healthcare (Waukesha, WI, USA), adds accuracy to different gel electrophoresis (DIGE) studies by enhancing the analytic capabilities of the software.

"EDA v1.0 is a powerful, state-of-the-art 2D [two dimensional] DIGE software solution that offers advanced statistical analysis in an easy-to-use format,” said Kumar Bala, global marketing manager, GE Healthcare. More...
"This valuable analytical tool will contribute to a better understanding of regulatory pathways and help proteomics researchers more rapidly and accurately identify proteins to discriminate between healthy and disease tissue samples and different disease states and tumor types.”

The software employs multivariate analysis and advanced clustering techniques to reveal patterns in protein expression data derived from 2D DIGE experiments. The software employs a data set as the basis for 2D gel analysis. Each set of data, defined as a group of spot maps with correlated protein spots, can be displayed in different ways, depending on the objectives of the study.

The DeCyder EDA is a suitable tool for conducing biologic variance analysis (BVA) and can answer questions such as the following. How many groups or classes exist in a specific data set? Do any of the protein spots demonstrate similar characteristics, implying co-regulation? Are there proteins or protein patterns that appear to be characteristic of a biologic or disease state? Are those specific proteins that might be useful for the development of a noninvasive diagnostic or prognostic test?

The software was specifically designed as a vital element of the Ettan 2D DIGE technology platform. It identifies and accurately matches multiplexed fluorescent images produced from Ettan DIGE gels.




Related Links:
GE Healthcare

New
Gold Member
Aspiration System
VACUSAFE
New
Gold Member
Clinical Chemistry Assay
Sorbitol Dehydrogenase (SDH)
New
HPV Molecular Test
BD Onclarity HPV Assay
New
Electrolyte Analyzer
BKE-B
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image

Urine-Based Multi-Cancer Screening Test Receives FDA Breakthrough Device Designation

Early detection across multiple cancers remains a major unmet need in population screening. Non-invasive approaches that can be delivered at scale may broaden access and shift diagnoses to earlier stages.... Read more

Molecular Diagnostics

view channel
Image: The new approach focuses on CpG DNA methylation, a chemical modification of cytosine and guanine bases, using tumor samples to develop a computational model that distinguishes among 21 cancer types (photo credet: 123RF)

Machine Learning Model Uses DNA Methylation to Predict Tumor Origin in Cancers of Unknown Primary

Cancers of unknown primary (CUP) are metastatic malignancies in which the primary site cannot be identified, complicating treatment selection. Many patients consequently receive broad, nonspecific chemotherapy... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.